Skip to Content
MilliporeSigma
All Photos(3)

Key Documents

View All Documentation

O7125

Sigma-Aldrich

L-Ornithine L-aspartate salt

≥98% (TLC)

Synonym(s):

(S)-2,5-Diaminopentanoic acid L-aspartate salt

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C9H19N3O6
CAS Number:
3230-94-2
Molecular Weight:
265.26
EC Number:
221-772-7
MDL number:
MFCD00058084
UNSPSC Code:
12352209
PubChem Substance ID:
329818920
NACRES:
NA.26

product name

L-Ornithine L-aspartate salt, powder

assay

≥98% (TLC)

Quality Level

200

form

powder

color

white to off-white

storage temp.

2-8°C

SMILES string

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

InChI

1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

InChI key

IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.

Other Notes

Product of arginine degradation by arginase

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mark J W McPhail et al.
Neurology, 80(11), 1041-1047 (2013-02-22)
To measure changes in psychometric state, neural activation, brain volume (BV), and cerebral metabolite concentrations during treatment of minimal hepatic encephalopathy. As proof of principle, 22 patients with well-compensated, biopsy-proven cirrhosis of differing etiology and previous minimal hepatic encephalopathy were
Janus P Ong et al.
Clinical drug investigation, 31(4), 213-220 (2011-01-07)
Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an important outcome measure for therapeutic intervention. The
Patrícia Coelho de Soárez et al.
Arquivos de gastroenterologia, 46(3), 241-247 (2009-11-18)
Experimental and clinical studies suggest that LOLA may have a favorable influence on hepatic encephalopathy due to the effect on the reduction of ammonia, and improvement of the symptoms and laboratory findings. To evaluate and to critically analyze the efficacy
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study
Babette Linde et al.
Medizinische Klinik (Munich, Germany : 1983), 102(10), 846-851 (2007-10-12)
Fulminate liver insufficiency can have many causes and is a challenge for differential diagnosis. A 39-year-old woman was admitted because of a nonitching macular-papular exanthema on both thighs with spreading to the trunk. In addition, the patient complained of dysphagia
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service